| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Ardisiacrispin B targets cancer cells through multiple mechanisms including ferroptosis and apoptosis. Ferroptosis is a form of regulated cell death characterized by iron-dependent lipid peroxidation, while apoptosis is a classical programmed cell death pathway. The compound's ability to overcome multi-factorial drug resistance makes it a valuable tool for studying drug resistance mechanisms in cancer.
|
|---|---|
| ln Vitro |
In cell-free biochemical systems, Ardisiacrispin B displays cytotoxic effects that can be attributed to its ability to induce ferroptosis and apoptosis. The compound's effects on lipid peroxidation and apoptotic signaling can be assessed in cell-free systems using purified components. The compound's ability to overcome drug resistance suggests it may act through pathways that are not affected by common resistance mechanisms.
|
| ln Vivo |
In cell-based assays, Ardisiacrispin B displays cytotoxic effects in multi-factorial drug resistant cancer cells. The compound has been evaluated on a panel of 9 cancer cell lines including various sensitive and drug-resistant phenotypes. The compound induces both ferroptotic and apoptotic cell death. It has shown activity against liver cancer, oral epithelial cancer, leukemia, cervical cancer, ovarian cancer, gastric cancer, and breast cancer.
|
| Enzyme Assay |
The cell-free assay for Ardisiacrispin B involves measuring its effects on lipid peroxidation and apoptotic signaling components. Ferroptosis can be assessed by measuring lipid peroxidation levels using biochemical assays. Apoptosis can be assessed by measuring caspase activity and PARP cleavage using purified enzymes and substrates. The compound's binding to target proteins can be studied using surface plasmon resonance or isothermal titration calorimetry.
|
| Cell Assay |
Cell-based assays for Ardisiacrispin B involve culturing cancer cell lines including drug-resistant variants and treating them with the compound at concentrations ranging from 0.1 to 100 μM. Cells are incubated for 24-72 hours, and cell viability is assessed using MTT or CCK-8 assays. Ferroptosis is assessed by measuring lipid peroxidation using fluorescent probes such as C11-BODIPY581/591. Apoptosis is evaluated by Annexin V staining, caspase activity assays, and PARP cleavage. The compound's ability to overcome drug resistance is assessed by comparing IC50 values in sensitive and resistant cell lines.
|
| Animal Protocol |
In animal models, Ardisiacrispin B could potentially be evaluated for its anti-tumor activity. Typical studies involve administration of the compound to tumor-bearing mice via intraperitoneal or intravenous routes. Tumor volumes are measured, and tissues are collected for analysis of ferroptosis markers, apoptosis markers, and signaling pathway modulation. The compound's ability to overcome drug resistance could be evaluated in drug-resistant tumor models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Ardisiacrispin B have not been extensively reported. As a triterpene saponin with a high molecular weight of approximately 1075.3 g/mol, the compound would be expected to have limited oral bioavailability and may require parenteral administration. The compound is soluble in chloroform, dichloromethane, ethyl acetate, DMSO, and acetone. It is typically stored desiccated at -20°C.
|
| Toxicity/Toxicokinetics |
Ardisiacrispin B is intended for research use only and lacks established toxicity profiles for therapeutic applications. Standard laboratory safety precautions should be observed when handling this natural product. As a saponin with cytotoxic activity, it may have effects on normal cells as well as cancer cells. The compound is typically stored desiccated at -20°C. Standard toxicity studies would be required for therapeutic development.
|
| References | |
| Additional Infomation |
Ardisiacrispin B has been reported to exist in Achyranthes bidentata, Achyranthes rubrum, and other organisms for which data are available.
Ardisiacrispin B is a research-grade natural product supplied for cancer research and drug resistance studies. It is not an approved pharmaceutical and has no clinical trial history. The compound is a naturally occurring oleanane-type triterpene saponin. It displays cytotoxic effects in multi-factorial drug resistant cancer cells via ferroptotic and apoptotic cell death. This product is intended for research use only. |
| Molecular Formula |
C53H86O22
|
|---|---|
| Molecular Weight |
1075.24
|
| Exact Mass |
1074.561
|
| CAS # |
112766-96-8
|
| PubChem CID |
10441164
|
| Appearance |
White to off-white solid powder
|
| Density |
1.468g/cm3
|
| LogP |
-0.6
|
| Hydrogen Bond Donor Count |
12
|
| Hydrogen Bond Acceptor Count |
22
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
75
|
| Complexity |
2060
|
| Defined Atom Stereocenter Count |
30
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2O[C@H]3CO[C@H]([C@@H]([C@H]3O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O[C@H]5CC[C@@]6([C@H]7CC[C@@]89[C@@H]1C[C@@](CC[C@]1(CO8)[C@@H](C[C@]9([C@@]7(CC[C@H]6C5(C)C)C)C)O)(C)C=O)C)CO)O)O)O)O)O
|
| InChi Key |
ZDIHSHLFPFGAGP-LLEYBADXSA-N
|
| InChi Code |
InChI=1S/C53H86O22/c1-23-32(58)36(62)39(65)43(69-23)75-42-38(64)34(60)25(19-55)71-46(42)72-26-20-67-45(41(35(26)61)74-44-40(66)37(63)33(59)24(18-54)70-44)73-31-10-11-49(5)27(47(31,2)3)8-12-50(6)28(49)9-13-53-29-16-48(4,21-56)14-15-52(29,22-68-53)30(57)17-51(50,53)7/h21,23-46,54-55,57-66H,8-20,22H2,1-7H3/t23-,24+,25+,26-,27-,28+,29+,30+,31-,32-,33+,34+,35-,36+,37-,38-,39+,40+,41+,42+,43-,44-,45-,46-,48-,49-,50+,51-,52+,53-/m0/s1
|
| Chemical Name |
(1S,2R,4S,5R,8R,10S,13R,14R,17S,18R,20S)-10-[(2S,3R,4S,5S)-5-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-4-hydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2-hydroxy-4,5,9,9,13,20-hexamethyl-24-oxahexacyclo[15.5.2.01,18.04,17.05,14.08,13]tetracosane-20-carbaldehyde
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9300 mL | 4.6501 mL | 9.3002 mL | |
| 5 mM | 0.1860 mL | 0.9300 mL | 1.8600 mL | |
| 10 mM | 0.0930 mL | 0.4650 mL | 0.9300 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
